Last updated: 2 April 2024 at 5:48pm EST

Steven Cobourn Net Worth



Steven Cobourn biography

Steven P. Cobourn CPA serves as Chief Financial Officer of the Company. Previously, he served as Chief Financial Officer of Vaccinex, Inc., a biotechnology company, from May 2014 to January 2018. Prior to joining Vaccinex, Mr. Cobourn was the Vice President of Finance and Treasurer of Otsuka America Pharmaceutical, Inc., a private pharmaceutical company, from 2003 to April 2014, and served in other roles at Otsuka America Pharmaceutical from 1993 to 2003. Prior to joining Otsuka America Pharmaceutical, Mr. Cobourn was a Certified Public Accountant at Hass & Company LLC, an accounting firm. Mr. Cobourn received a B.S. in business administration from Drexel University and is a Certified Public Accountant.

What is the salary of Steven Cobourn?

As the Chief Financial Officer of Nextcure Inc, the total compensation of Steven Cobourn at Nextcure Inc is $993,341. There are no executives at Nextcure Inc getting paid more.



How old is Steven Cobourn?

Steven Cobourn is 57, he's been the Chief Financial Officer of Nextcure Inc since 2018. There are 15 older and 6 younger executives at Nextcure Inc. The oldest executive at Nextcure Inc is David Kabakoff, 72, who is the Independent Chairman of the Board.

What's Steven Cobourn's mailing address?

Steven's mailing address filed with the SEC is C/O NEXTCURE, INC., 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE, MD, 20705.

Insiders trading at Nextcure Inc

Over the last 6 years, insiders at Nextcure Inc have traded over $0 worth of Nextcure Inc stock and bought 1,475,000 units worth $25,387,500 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Chau Quang Khuong oraz Timothy M Shannon. On average, Nextcure Inc executives and independent directors trade stock every 48 days with the average trade being worth of $233,653. The most recent stock trade was executed by Kevin N. Heller on 14 July 2020, trading 27,229 units of NXTC stock currently worth $48,195.



What does Nextcure Inc do?

nextcure, inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. its lead product candidate is nc318, which is in phase 2 clinical trials for the treatment of advanced or metastatic solid tumors. the company is also developing nc410, is a novel immunomedicine designed to block immune suppression mediated by an immune modulator called leukocyte-associated immunoglobulin-like receptor 1. its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules that targets a novel member of the b7-family of immunomodulatory proteins; and an antibody in preclinical development targeting an immune modulator that is expressed in inflamed tissue and the tumor microenvironment in various tumor types. nextcure, inc. has a license agreement with yale university; and a research and development col



What does Nextcure Inc's logo look like?

Nextcure Inc logo

Nextcure Inc executives and stock owners

Nextcure Inc executives and other stock owners filed with the SEC include: